Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Pifithrin-α hydrobromide

Pifithrin-α hydrobromide
Contact us for more batch information
Select Batch
Purity:100%
Resource Download

Pifithrin-α hydrobromide

Catalog No. T2707Cas No. 63208-82-2
Pifithrin-α hydrobromide (Pifithrin-α hydrobromide) is a p53 inhibitor, inhibiting p53-dependent transactivation of p53-responsive genes.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
2 mg$33In Stock
5 mg$52In Stock
10 mg$81In Stock
25 mg$180In Stock
50 mg$293In Stock
100 mg$438In Stock
1 mL x 10 mM (in DMSO)$54In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Pifithrin-α hydrobromide"

Product Introduction

Bioactivity
Description
Pifithrin-α hydrobromide (Pifithrin-α hydrobromide) is a p53 inhibitor, inhibiting p53-dependent transactivation of p53-responsive genes.
In vitro
Intraperitoneal injection of 3.6 μg/kg Pifithrin-α in mice significantly inhibited Dex-induced thymic atrophy. Compared to the control group, Pifithrin-α (2 mg/kg) notably decreased the extent of motor dysfunction in rats with transient cerebral artery occlusion. Administration of Pifithrin-α (2 mg/kg i.p.) 30 minutes before treatment of cerebral artery occlusion in mice reduced ischemic brain damage and shielded hippocampal neurons from excitotoxicity damage. In C57BL and Balb/c mice, intraperitoneal injection of 2.2 mg/kg Pifithrin-α completely protected the mice against the lethal effects of 60% mortality gamma-ray irradiation. Pifithrin-α was observed to substantially lower cellular apoptosis in rats, evidenced by Tunel and caspase 3 staining. When administered within one hour after a stroke, animals treated with Pifithrin-α exhibited fewer motor dysfunctions and smaller infarcts. After 7 days of treatment with Pifithrin-α, rats showed significantly reduced scores of motor dysfunction compared to the placebo control group.
In vivo
At a concentration of 10 μM, Pifithrin-α inhibits apoptosis in C8 cells induced by Dox, Etoposide, Taxol, and Cytosine arabinoside. It also reduces activation of the heat shock transcription factor and enhances cell sensitivity to heat, lowers glucocorticoid receptor activation in HeLa cells, and protects murine thymocytes from apoptosis induced by Dexamethasone. Concentrations between 100–200 nM of Pifithrin-α completely block the increase in p53 DNA binding levels and the p53-responsive gene Bax in hippocampal cells induced by Camptothecin, while 200 nM safeguards cultured hippocampal neurons from death caused by DNA damage agents. Furthermore, 200 μM Pifithrin-α stabilizes mitochondrial function, inhibits caspase activation, and shields hippocampal neurons from death induced by glutamate and β-amyloid peptide. Pifithrin-α prevents the p53-dependent growth inhibition in human diploid fibroblasts following DNA damage, though it does not affect fibroblasts lacking p53. It can regulate the nuclear import and export of p53, or both, and decrease nuclear p53 stability. Pifithrin-α inhibits signals from heat shock and glucocorticoid receptors without affecting NF-κB signaling.
Kinase Assay
The ligand binding competition assays are performed. Cytosolic cell extracts from Hepa-1 cells are generated by the resuspension of the cell pellets in HEDG buffer [25 mM Hepes, 1 mM EDTA, 1 mM dithiothreitol, and 10% (v/v) glycerol, pH 7.5] containing 0.4 mM leupeptin, 4 mg/mL aprotinin, and 0.3 mM phenylmethylsulfonyl fluoride, homogenization, and centrifugation at 100,000 g for 45 min. Aliquots of the supernatant (120 μg) are incubated at room temperature for 2 h with the indicated concentrations of Pifithrin-α in the presence of 3 nM [3H]TCDD in HEDG buffer. After incubation on ice with hydroxyapatite for 30 min, HEDG buffer with 0.5% Tween 80 is added. The samples are centrifuged, washed twice, resuspended in 0.2 mL of scintillation fluid, and subjected to scintillation counting. Nonspecific binding is determined using a 150-fold molar excess of TCDF and subtracted from the total binding to obtain the specific binding. The specific binding is reported relative to [3H]TCDD alone[2].
Cell Research
At the end of cell treatments, the number of attached cells is estimated by staining with 0.25% crystal violet in 50% methanol, followed by elution of the dye with 1% SDS. Optical density (530 nm) reflecting the number of stained cells is determined with a Bio-Tek EL311 microplate reader. Cell viability in suspension of short term culture of primary thymocytes is determined by their staining with 0.1% of methyl blue and microscopic counting of blue (dead) cells.(Only for Reference)
AliasPifithrin hydrobromide, Pifithrin-α (PFTα) HBr, Pifithrin-α, PFTα, PFTα hydrobromide
Chemical Properties
Molecular Weight367.3
FormulaC16H18N2OS·HBr
Cas No.63208-82-2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 36.7 mg/mL (100 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.7226 mL13.6129 mL27.2257 mL136.1285 mL
5 mM0.5445 mL2.7226 mL5.4451 mL27.2257 mL
10 mM0.2723 mL1.3613 mL2.7226 mL13.6129 mL
20 mM0.1361 mL0.6806 mL1.3613 mL6.8064 mL
50 mM0.0545 mL0.2723 mL0.5445 mL2.7226 mL
100 mM0.0272 mL0.1361 mL0.2723 mL1.3613 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords